Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma.

abstract：:The role of allogeneic hematopoietic SCT (allo-HCT) in multiple myeloma (MM) remains controversial. A total of 58 patients received an allo-HCT (25 of them with myeloablative conditioning-allo-MAC-and 33 with reduced-intensity conditioning-allo-RIC) at our institution over a 28-year period. The CR rate for allo-MAC wa...

journal_title：Bone marrow transplantation

authors： Rosiñol L,Jiménez R,Rovira M,Martínez C,Fernández-Avilés F,Marín P,Suárez-Lledó M,Gutiérrez-García G,Fernández de Larrea C,Carreras E,Urbano-Ispizua A,Bladé J

更新日期：2015-05-01 00:00:00

abstract：:The human recombinant G-CSF filgrastim has been widely used for the mobilization of CD34(+) stem cells of healthy donors (HD). In 2008, the G-CSF biosimilar XM02 (Ratiograstim, Tevagrastim and Biograstim) was approved by the European Medicines Agency (EMA) for the mobilization of PBSC. However, there is limited experi...

journal_title：Bone marrow transplantation

authors： Schmitt M,Xu X,Hilgendorf I,Schneider C,Borchert K,Gläser D,Freund M,Schmitt A

更新日期：2013-07-01 00:00:00

abstract：:Recent studies from this laboratory have shown that unmanipulated, MHC-mismatched allogeneic bone marrow (BM) engrafts and produces complete allogeneic chimerism when administered to recipient mice 8 days following lethal irradiation and reconstitution with T cell-depleted (TCD) syngeneic bone marrow. Host lymphopoiet...

journal_title：Bone marrow transplantation

authors： Chester CH,Sykes M,Sachs DH

更新日期：1989-03-01 00:00:00

abstract：:The transfer of cytotoxic effector cells reduces the risk of relapse after allogeneic BMT. Two murine leukemia cell lines, A20 (B lymphocytic) and WEHI-3 (myelomonocytic), were used to investigate antileukemic effector mechanisms operating independently from graft-versus-host disease (GVHD). Different results were obt...

journal_title：Bone marrow transplantation

authors： Uharek L,Glass B,Gaska T,Zeiss M,Gassmann W,Löffler H,Müller-Ruchholtz W

更新日期：1993-01-01 00:00:00

abstract：:In an otherwise eligible patient with relapsed lymphoma, inadequate mobilization of hematopoietic stem cells (HSCs) is a limiting factor to proceeding with an autologous hematopoietic cell transplantation (auto-HCT). Multiple strategies have been used to mobilize an adequate number of HSCs with no obvious front-line s...

journal_title：Bone marrow transplantation

authors： Haverkos BM,Huang Y,Elder P,O'Donnell L,Scholl D,Whittaker B,Vasu S,Penza S,Andritsos LA,Devine SM,Jaglowski SM

更新日期：2017-04-01 00:00:00

abstract：:For several haematological malignancies, allogeneic stem cell transplantation is the treatment of choice. In most cases an HLA-identical sibling is required. If the mother of a patient is pregnant, cord blood from a related donor, which can be used for stem cell transplantation, might be obtainable in the near future....

journal_title：Bone marrow transplantation

authors： van den Berg H,Verjaal M,Boer K,Lardy NM

更新日期：2000-03-01 00:00:00

abstract：:Pure red cell aplasia (PRCA) is characterized by a selective marrow aplasia of the erythroid compartment. Immunosuppressive therapy achieves good results in about 25% of cases, but relapses are frequent. Autologous or allogeneic haematopoietic stem cell transplantation (HSCT) may be valuable in selected patients. Here...

journal_title：Bone marrow transplantation

authors： Musso M,Porretto F,Crescimanno A,Polizzi V,Scalone R

更新日期：2004-04-01 00:00:00

abstract：:Children with multisystem Langerhans cell histiocytosis (LCH) and risk organ involvement who fail to respond to conventional chemotherapy have an extremely poor prognosis. Myeloablative stem cell transplantation (SCT) as a possible salvage approach for these patients has been associated with a high risk of transplant-...

journal_title：Bone marrow transplantation

authors： Steiner M,Matthes-Martin S,Attarbaschi A,Minkov M,Grois N,Unger E,Holter W,Vormoor J,Wawer A,Ouachee M,Woessmann W,Gadner H

更新日期：2005-08-01 00:00:00

abstract：:Nine patients with advanced Hodgkin's lymphoma (HL) who had undergone allogeneic stem cell transplantation (allo-SCT) received donor leukocyte infusions (DLIs) for treatment of persistent or progressive disease (PD). A total of 15 DLIs were performed, with four patients receiving more than one DLI. In four patients, p...

journal_title：Bone marrow transplantation

authors： Anderlini P,Acholonu SA,Okoroji GJ,Andersson BS,Couriel DR,De Lima MJ,Donato ML,Khouri IF,Giralt SA,Ueno NT,Champlin RE

更新日期：2004-09-01 00:00:00

abstract：:Post transplantation constrictive bronchiolitis (PTCB) is the most common pulmonary complication among long-term survivors of allogeneic hematopoietic stem cell transplantation (HSCT). It is a late manifestation of GVHD. Its treatment with high-dose systemic corticosteroids and other immunosuppressive regimens is asso...

journal_title：Bone marrow transplantation

authors： Bashoura L,Gupta S,Jain A,Couriel DR,Komanduri KV,Eapen GA,Safdar A,Broglio KR,Adachi R,Dickey BF

更新日期：2008-01-01 00:00:00

abstract：:To augment graft cell dose, we evaluated the safety of the combined transplantation of two partially HLA-matched umbilical cord blood (UCB) units. Five patients with transfusion-dependent thalassemia, median age 11.1 years (range 10-13.1), received 2 UCB units after myeloablative conditioning. Cord blood units were a ...

journal_title：Bone marrow transplantation

authors： Jaing TH,Yang CP,Hung IJ,Chen SH,Sun CF,Chow R

更新日期：2007-08-01 00:00:00

abstract：:Severe veno-occlusive disease (VOD), characterised by elevated serum bilirubin levels, is a known complication in the first 3 weeks after peripheral blood stem cell transplantation (PBSCT). Severe VOD is associated with capillary leakage and multiple organ dysfunction and leads to high mortality. We report a 17-year-o...

journal_title：Bone marrow transplantation

authors： Heying R,Nürnberger W,Spiekerkötter U,Göbel U

更新日期：1998-05-01 00:00:00

abstract：:The use of cytokines following bone marrow transplantation has become an area of increasing controversy with specific regard to indication, efficacy and cost. This review will attempt to summarize cytokine data in both adult and pediatric transplantation. Indications for cytokines following transplantation will be pre...

journal_title：Bone marrow transplantation

authors： Weinthal JA

更新日期：1996-12-01 00:00:00

abstract：:We investigated the nature of hemostatic alterations occurring after bone marrow transplantation. In 45 patients, we evaluated the coagulation parameters, naturally occurring anticoagulants and thrombomodulin at days +15 and +22 after conditioning therapy. It was observed that endothelial cell damage is a central path...

journal_title：Bone marrow transplantation

authors： Testa S,Manna A,Porcellini A,Maffi F,Morstabilini G,Denti N,Macchi S,Rosti G,Porcellini G,Cassi D,Ferrari L

更新日期：1996-08-01 00:00:00

abstract：:Little is known about the cell types or mechanisms that underlie the engraftment process. Here, we have examined parameters affecting the engraftment of purified human Lin-CD34+CD38- normal and AML cells transplanted at limiting doses into NOD/SCID recipients. Mice transplanted with 500 to 1000 Lin-CD34+CD38- cord blo...

journal_title：Bone marrow transplantation

authors： Bonnet D,Bhatia M,Wang JC,Kapp U,Dick JE

更新日期：1999-02-01 00:00:00

abstract：:Microangiopathic hemolytic anemia (MAHA) is a well-described complication of stem cell transplantation. Plasmapheresis is one modality utilized as therapy for patients who develop this complication. However, plasmapheresis may alter whole blood levels of certain medications and its effect on tacrolimus in bone marrow ...

journal_title：Bone marrow transplantation

authors： Hale GA,Reece DE,Munn RK,Kniska AB,Phillips GL

更新日期：2000-02-01 00:00:00

abstract：:Data on 477 patients with hematologic malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings were analyzed for correlation between donor-recipient ABO blood group incompatibility and the development of elevated bilirubin levels (over 17 mmol/l) after transplantation. The median bili...

journal_title：Bone marrow transplantation

authors： Mehta J,Powles R,Horton C,Milan S,Singhal S,Treleaven J

更新日期：1995-06-01 00:00:00

abstract：:The aim of the present study was to explore whether there is enhanced endothelial dysfunction in patients developing acute GvHD (aGvHD) after allogeneic hematopoietic cell transplantation (allo-HCT) and to identify biomarkers with predictive and/or diagnostic value. In in vitro experiments, endothelial cells (ECs) wer...

journal_title：Bone marrow transplantation

authors： Mir E,Palomo M,Rovira M,Pereira A,Escolar G,Penack O,Holler E,Carreras E,Diaz-Ricart M

更新日期：2017-09-01 00:00:00

abstract：:Haematopoietic stem and progenitor cells (HSPC) mobilization, using cytokine-alone, is a well-tolerated regimen with predictable mobilization kinetics. Single-dose pegfilgrastim mobilizes HSPC efficiently; however, there is surprisingly little comparative data on its use without chemotherapy for HSPC mobilization. Peg...

journal_title：Bone marrow transplantation

authors： Herbert KE,Gambell P,Link EK,Mouminoglu A,Wall DM,Harrison SJ,Ritchie DS,Seymour JF,Prince HM

更新日期：2013-03-01 00:00:00

abstract：:Transplantation-associated thrombotic microangiopathy (TA-TMA) is a feared complication of allogeneic hematopoietic SCT (HSCT) owing to its high mortality rate. The use of calcineurin inhibitors or sirolimus (SIR) for GVHD prophylaxis has been suggested as a potential risk factor. However, the impact of tacrolimus (TA...

journal_title：Bone marrow transplantation

authors： Labrador J,López-Corral L,López-Godino O,Vázquez L,Cabrero-Calvo M,Pérez-López R,Díez-Campelo M,Sánchez-Guijo F,Pérez-López E,Guerrero C,Alberca I,Del Cañizo MC,Pérez-Simón JA,González-Porras JR,Caballero D

更新日期：2014-05-01 00:00:00

abstract：:Two women suffering from severe aplastic anemia were treated by bone marrow transplantation (BMT). They became pregnant 17 and 40 months after the procedure. During the first 20 weeks of pregnancy, one of them continued to receive cyclosporin A (CSA) to prevent graft-versus-host disease. Her CSA serum levels during th...

journal_title：Bone marrow transplantation

authors： Schmidt H,Ehninger G,Dopfer R,Waller HD

更新日期：1987-10-01 00:00:00

abstract：:Community-acquired respiratory virus (RV) infections are an important cause of disease in immunocompromised adults with cancer. To investigate the viral etiology, incidence, clinical presentation, and outcome of RV infections in an outpatient cohort of adult bone marrow or peripheral blood stem cell transplant (SCT) r...

journal_title：Bone marrow transplantation

authors： Roghmann M,Ball K,Erdman D,Lovchik J,Anderson LJ,Edelman R

更新日期：2003-12-01 00:00:00

abstract：:We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group ...

journal_title：Bone marrow transplantation

authors： Wang Y,Ogawa Y,Dogru M,Kawai M,Tatematsu Y,Uchino M,Okada N,Igarashi A,Kujira A,Fujishima H,Okamoto S,Shimazaki J,Tsubota K

更新日期：2008-02-01 00:00:00

abstract：:Repeated high-dose (HD) chemotherapy with peripheral blood stem cell (PBSC) transplantation is a new modality aimed at increasing both the dose and its intensity in the treatment of chemosensitive tumours. The aim of this study was to evaluate the tolerance, pharmacokinetics (PK) and pharmacodynamics (PD) of HD single...

journal_title：Bone marrow transplantation

authors： Vassal G,Tranchand B,Valteau-Couanet D,Mahé C,Couanet D,Schoeppfer C,Grill J,Kalifa C,Hill C,Ardiet C,Hartmann O

更新日期：2001-03-01 00:00:00

abstract：:We evaluated the efficacy and safety of the conditioning regimen that consisted of TBI and melphalan (L-PAM), followed by hematopoietic SCT (HSCT) in 23 children with advanced hematological malignancies. The median age at HSCT was 9 (range, 2-15) years. The underlying diseases were ALL in 16 patients (5 in CR2, 3 in C...

journal_title：Bone marrow transplantation

authors： Inagaki J,Nagatoshi Y,Sakiyama M,Nomura Y,Teranishi H,Sasaki T,Okamura J

更新日期：2011-08-01 00:00:00

abstract：:A phase I/II trial evaluated early administration and dose escalation of interleukin (IL)-2 with granulocyte macrophage colony stimulating factor (GM-CSF) post-transplant. Following melphalan (200 mg/m(2)) and an autologous transplant, IL-2 was initiated (day 0) and continued for 4 weeks. GM-CSF (250 mcg/m(2)/day) beg...

journal_title：Bone marrow transplantation

authors： Meehan KR,Wu J,Bengtson E,Hill J,Ely P,Szczepiorkowski Z,Kendall M,Ernstoff MS

更新日期：2007-06-01 00:00:00

abstract：:Data on long-term follow-up of donors for hematopoietic stem cell transplantation (HSCT) are limited. Donors of 612 adult allogeneic HSCT were studied, at a median of 81 (14-181) months post-HSC donation. Nine donors had severe health problems. Five donors died from aggressive malignancies or terminal illness, at a me...

journal_title：Bone marrow transplantation

authors： Au WY,Lie AK,Cheng JW,Liang R,Kwong YL

更新日期：2006-03-01 00:00:00

abstract：:We review here the functional and kinetic characteristics of highly purified hematopoietic CD34+ mobilized into peripheral blood (PB) by granulocyte colony-stimulating factor (G-CSF) with or without chemotherapy for autologous or allogeneic transplantation. Circulating CD34+ cells were evaluated for their colony-formi...

journal_title：Bone marrow transplantation

authors： Lemoli RM,Tafuri A,Fortuna A,Catani L,Rondelli D,Ratta M,Tura S

更新日期：1998-12-01 00:00:00

abstract：:Preparative regimens without total body irradiation (TBI) have been reported for alternative donor hemopoietic stem cell transplants (HSCT). Between 7 September 1994 and 7 June 1999 48 patients with advanced hematologic malignancies were conditioned with thiotepa (THIO) 15 mg/kg, cyclophosphamide (CY) 150 mg/kg and an...

journal_title：Bone marrow transplantation

authors： Lamparelli T,van Lint MT,Gualandi F,Raiola AM,Barbanti M,Sacchi N,Ficai G,Ghinatti C,Bregante S,Berisso G,Dominietto A,Di Grazia C,Bruno B,Sessarego M,Casarino L,Verdiani S,Bacigalupo A

更新日期：2000-12-01 00:00:00

abstract：:Certain leukemias have a high relapse risk even after allo-SCT, and GVHD prophylaxis with calcineurin inhibitors (CNIs) may interfere with a possible GVL effect. Therefore, we replaced CYA by sirolimus in patients with high relapse risk. In contrast to CNIs, sirolimus promotes the generation of regulatory T-cells and ...

journal_title：Bone marrow transplantation

authors： Schleuning M,Judith D,Jedlickova Z,Stübig T,Heshmat M,Baurmann H,Schwerdtfeger R

更新日期：2009-05-01 00:00:00